Epigenomics of human embryonic stem cells and induced pluripotent stem cells: insights into pluripotency and implications for disease

被引:0
|
作者
Alvaro Rada-Iglesias
Joanna Wysocka
机构
[1] Stanford University School of Medicine,Department of Chemical and Systems Biology
[2] Stanford University School of Medicine,Department of Developmental Biology
来源
关键词
hESC Line; iPSC Line; Chromatin Feature; Histone PTMs; Chromatin Signature;
D O I
暂无
中图分类号
学科分类号
摘要
Human pluripotent cells such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) and their in vitro differentiation models hold great promise for regenerative medicine as they provide both a model for investigating mechanisms underlying human development and disease and a potential source of replacement cells in cellular transplantation approaches. The remarkable developmental plasticity of pluripotent cells is reflected in their unique chromatin marking and organization patterns, or epigenomes. Pluripotent cell epigenomes must organize genetic information in a way that is compatible with both the maintenance of self-renewal programs and the retention of multilineage differentiation potential. In this review, we give a brief overview of the recent technological advances in genomics that are allowing scientists to characterize and compare epigenomes of different cell types at an unprecedented scale and resolution. We then discuss how utilizing these technologies for studies of hESCs has demonstrated that certain chromatin features, including bivalent promoters, poised enhancers, and unique DNA modification patterns, are particularly pervasive in hESCs compared with differentiated cell types. We outline these unique characteristics and discuss the extent to which they are recapitulated in iPSCs. Finally, we envision broad applications of epigenomics in characterizing the quality and differentiation potential of individual pluripotent lines, and we discuss how epigenomic profiling of regulatory elements in hESCs, iPSCs and their derivatives can improve our understanding of complex human diseases and their underlying genetic variants.
引用
收藏
相关论文
共 50 条
  • [1] Epigenomics of human embryonic stem cells and induced pluripotent stem cells: insights into pluripotency and implications for disease
    Rada-Iglesias, Alvaro
    Wysocka, Joanna
    GENOME MEDICINE, 2011, 3
  • [2] A COMPARATIVE STUDY OF PLURIPOTENCY MARKERS IN EMBRYONIC STEM CELLS AND INDUCED PLURIPOTENT STEM CELLS
    Julien, D. C.
    Verma, K.
    Zambidis, E.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (01) : 204 - 204
  • [3] Pluripotency of human embryonic and induced pluripotent stem cells for cardiac and vascular regeneration
    Boheler, Kenneth R.
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (01) : 23 - 29
  • [4] Pluripotency of Induced Pluripotent Stem Cells
    Chunjing Feng
    Yun-Dan Jia
    Xiao-Yang Zhao
    Genomics,Proteomics & Bioinformatics, 2013, 11 (05) : 299 - 303
  • [5] Pluripotency of induced pluripotent stem cells
    Lan Kang and Shaorong Gao National Institute of Biological Sciences
    JournalofAnimalScienceandBiotechnology, 2012, 3 (01) : 3 - 9
  • [6] Glycomics of human embryonic stem cells and human induced pluripotent stem cells
    Jun-ichi Furukawa
    Kazue Okada
    Yasuro Shinohara
    Glycoconjugate Journal, 2016, 33 : 707 - 715
  • [7] Glycomics of human embryonic stem cells and human induced pluripotent stem cells
    Jun-ichi Furukawa
    Kazue Okada
    Yasuro Shinohara
    Glycoconjugate Journal, 2017, 34 : 807 - 815
  • [8] Glycomics of human embryonic stem cells and human induced pluripotent stem cells
    Furukawa, Jun-ichi
    Okada, Kazue
    Shinohara, Yasuro
    GLYCOCONJUGATE JOURNAL, 2016, 33 (05) : 707 - 715
  • [9] Pluripotency of induced pluripotent stem cells
    Lan Kang
    Shaorong Gao
    Journal of Animal Science and Biotechnology, 3
  • [10] Glycomics of human embryonic stem cells and human induced pluripotent stem cells
    Furukawa, Jun-ichi
    Okada, Kazue
    Shinohara, Yasuro
    GLYCOCONJUGATE JOURNAL, 2017, 34 (06) : 807 - 815